Co-Diagnostics, Inc. Performs Analysis of Chikungunya Co-Primers® to Confirm Reactivity Against Known Virus Strains
Rhea-AI Summary
Co-Diagnostics (NASDAQ:CODX) has completed an in silico analysis of its Co-Primers®-based PCR tests for chikungunya virus (CHIKV) detection. The analysis demonstrated high homology against over 1,200 CHIKV sequences and confirmed reactivity against recent virus strains.
The company's Logix Smart® ZDC Test, CE-marked since 2019, can detect and differentiate between Zika, dengue, and chikungunya viral RNA. Additionally, CODX's Vector Smart® VZDC Test is used by 30 mosquito abatement districts across 20 U.S. states for environmental testing. The company's Indian joint venture, CoSara Diagnostics, has received clearance to manufacture and sell its SaraGene™ Dengue and Chikungunya Multiplex RT-PCR test.
Positive
- None.
Negative
- Logix Smart ZDC Test not approved for sale in the United States
- Primary markets concentrated in low- and middle-income countries with economic constraints
News Market Reaction
On the day this news was published, CODX gained 12.20%, reflecting a significant positive market reaction. Argus tracked a peak move of +10.5% during that session. Argus tracked a trough of -3.0% from its starting point during tracking. Our momentum scanner triggered 14 alerts that day, indicating notable trading interest and price volatility. This price movement added approximately $2M to the company's valuation, bringing the market cap to $14M at that time.
Data tracked by StockTitan Argus on the day of publication.
As of July, there have been nearly 250,000 cases and 90 deaths from CHIKV worldwide, primarily concentrated in
Chikungunya imposes a significant economic burden, especially in low- and middle-income countries. Long-term consequences for the patient are also common, particularly joint pain that can be debilitating, with
The Co-Diagnostics Logix Smart® ZDC Test* received CE-marking regulatory clearance in 2019 to be sold as an in vitro diagnostic ("IVD") for the viruses that cause Zika, dengue and chikungunya. The test functions via the Company's patented Co-Primers technology and a single-step reverse transcriptase real-time PCR process to detect and differentiate between the viral RNA of Zika, dengue (all 4 serotypes), and chikungunya in blood drawn from patients. It is available for markets that accept CE-marking as valid regulatory clearance, pending local product registration requirements.
Differentiating CHIKV cases from other infections with similar symptoms, such as dengue, helps physicians avoid administering certain pain and fever medications that can increase risk of bleeding and be life-threatening in patients with severe dengue infections. As an arbovirus spread by mosquitoes, accurate diagnosis is also vital to indicate to an infected patient that they should take additional precautions to limit contact with mosquitoes, to prevent further spread of the virus.
Co-Dx also offers its Co-Primers-based environmental use only Vector Smart® VZDC Test to mosquito abatement districts ("MADs"), as part of its suite of vector control tests used by around 30 MADs across approximately 20 U.S. states to identify pathogens such as Zika, dengue, chikungunya, West Nile virus,
Co-Diagnostics Indian joint venture CoSara Diagnostics Pvt Ltd received clearance in October 2021 by Indian authorities to manufacture and sell its SaraGene™ Dengue and Chikungunya Multiplex RT-PCR test as an IVD, which is also built on the Company's Co-Primers platform technology.
*This product is for export only and is not for sale in
About Co-Diagnostics, Inc.:
Co-Diagnostics, Inc., a
Forward-Looking Statements:
This press release contains forward-looking statements. Forward-looking statements can be identified by words such as "believes," "expects," "estimates," "intends," "may," "plans," "will" and similar expressions, or the negative of these words. Such forward-looking statements are based on facts and conditions as they exist at the time such statements are made and predictions as to future facts and conditions. Forward-looking statements in this release include statements regarding our belief that Co-Primers tests for chikungunya can detect known recent strains of the virus as cases spike. Forward-looking statements are subject to inherent uncertainties, risks and changes in circumstances. Actual results may differ materially from those contemplated or anticipated by such forward-looking statements. Readers of this press release are cautioned not to place undue reliance on any forward-looking statements. There can be no assurance that any of the anticipated results will occur on a timely basis or at all due to certain risks and uncertainties, a discussion of which can be found in our Risk Factors disclosure in our Annual Report on Form 10-K, filed with the Securities and Exchange Commission (SEC) on March 27, 2025, and in our other filings with the SEC. The Company does not undertake any obligation to update any forward-looking statement relating to matters discussed in this press release, except as may be required by applicable securities laws.
View original content to download multimedia:https://www.prnewswire.com/news-releases/co-diagnostics-inc-performs-analysis-of-chikungunya-co-primers-to-confirm-reactivity-against-known-virus-strains-302553601.html
SOURCE Co-Diagnostics
FAQ
What did Co-Diagnostics (CODX) announce about its chikungunya virus test?
Where is Co-Diagnostics' Logix Smart ZDC Test currently approved for use?
How many U.S. states use Co-Diagnostics' Vector Smart VZDC Test?
What is the market size for Co-Diagnostics' chikungunya virus test?
What regulatory approvals does Co-Diagnostics have for its chikungunya tests?
